Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piotr Rutkowski

Showing results (31-40 of 491) with videos related to

Pageof 50
Sort By:
Langmuir : the ACS Journal of Surfaces and Colloids|July 21, 2018
Micropore Size Distribution and Surface Characteristics Co-influence on 4-Chlorophenol Adsorption Mechanism from Organic SolventsEwa Lorenc-Grabowska, Piotr Rutkowski
Cancer Treatment Reviews|August 13, 2013
Adherence to imatinib therapy in patients with gastrointestinal stromal tumorsJean-Yves Blay, Piotr Rutkowski
Polish Journal of Pathology : Official Journal of the Polish Society of Pathologists|June 5, 2014
[Molecular-clinical issues of gastrointestinal stromal tumors]Piotr Rutkowski, Zbigniew I Nowecki
Expert Review of Anticancer Therapy|August 13, 2023
Pembrolizumab for the adjuvant treatment of IIB or IIC melanomaPiotr Rutkowski, Anna M Czarnecka
Expert Review of Anticancer Therapy|June 2, 2015
Current treatment options for dermatofibrosarcoma protuberansPiotr Rutkowski, Maria Debiec-Rychter
BMC Medicine|June 3, 2017
Spotlight on landmark oncology trials: the latest evidence and novel trial designsHelena Earl, Stefano Molica, Piotr Rutkowski
European Journal of Cancer (Oxford, England : 1990)|November 12, 2022
Challenges of oncological care in Poland hosting Ukrainian refugees of warLucjan Wyrwicz, Jan Walewski, Piotr Rutkowski
European Journal of Cancer (Oxford, England : 1990)|September 16, 2025
Response to letter Re: Avelumab plus axitinib in patients with advanced gastrointestinal stromal tumorPiotr Rutkowski, Katarzyna Kozak, Paweł Teterycz
The International Journal of Biochemistry & Cell Biology|April 8, 2014
Genetics of rare mesenchymal tumors: implications for targeted treatment in DFSP, ASPS, CCS, GCTB and PEComaPiotr Rutkowski, Joanna Przybył, Tomasz Świtaj
Expert Opinion on Pharmacotherapy|April 12, 2024
Recent advances in tyrosine kinase inhibitors VEGFR 1-3 for the treatment of advanced metastatic melanomaPaweł Sobczuk, Michał Cholewiński, Piotr Rutkowski
Pageof 50

Showing results (31-40 of 491) with videos related to

Sort By:
Pageof 50
Langmuir : the ACS Journal of Surfaces and Colloids|July 21, 2018
Micropore Size Distribution and Surface Characteristics Co-influence on 4-Chlorophenol Adsorption Mechanism from Organic SolventsEwa Lorenc-Grabowska, Piotr Rutkowski
Cancer Treatment Reviews|August 13, 2013
Adherence to imatinib therapy in patients with gastrointestinal stromal tumorsJean-Yves Blay, Piotr Rutkowski
Polish Journal of Pathology : Official Journal of the Polish Society of Pathologists|June 5, 2014
[Molecular-clinical issues of gastrointestinal stromal tumors]Piotr Rutkowski, Zbigniew I Nowecki
Expert Review of Anticancer Therapy|August 13, 2023
Pembrolizumab for the adjuvant treatment of IIB or IIC melanomaPiotr Rutkowski, Anna M Czarnecka
Expert Review of Anticancer Therapy|June 2, 2015
Current treatment options for dermatofibrosarcoma protuberansPiotr Rutkowski, Maria Debiec-Rychter
BMC Medicine|June 3, 2017
Spotlight on landmark oncology trials: the latest evidence and novel trial designsHelena Earl, Stefano Molica, Piotr Rutkowski
European Journal of Cancer (Oxford, England : 1990)|November 12, 2022
Challenges of oncological care in Poland hosting Ukrainian refugees of warLucjan Wyrwicz, Jan Walewski, Piotr Rutkowski
European Journal of Cancer (Oxford, England : 1990)|September 16, 2025
Response to letter Re: Avelumab plus axitinib in patients with advanced gastrointestinal stromal tumorPiotr Rutkowski, Katarzyna Kozak, Paweł Teterycz
The International Journal of Biochemistry & Cell Biology|April 8, 2014
Genetics of rare mesenchymal tumors: implications for targeted treatment in DFSP, ASPS, CCS, GCTB and PEComaPiotr Rutkowski, Joanna Przybył, Tomasz Świtaj
Expert Opinion on Pharmacotherapy|April 12, 2024
Recent advances in tyrosine kinase inhibitors VEGFR 1-3 for the treatment of advanced metastatic melanomaPaweł Sobczuk, Michał Cholewiński, Piotr Rutkowski
Pageof 50